TORONTO, Aug. 24, 2006 (PRIMEZONE) -- Swiss Medica, Inc. (OTCBB:SWME) announced today that Golf Magazine has distributed over 400,000 O24 Pain Neutralizer information postcards with an attached free sample towelette as an insert to their 55+ year old magazine subscribers in the United States. The sample towelettes were included in the September 2006 issue of Golf Magazine. Golf Magazine is the world's most widely read golf publication, and is read by millions of golfers each month.
Grant Johnson, President and COO of Swiss Medica stated that "While the magazine has only been in circulation for less than a week, we are already seeing a dramatic pick-up on our www.024zone.com website and 1-877 toll-free customer care line regarding where they can buy O24."
O24 is also being sampled to over 100,000 golfers this summer at golf tournaments in Canada and in clubhouses including Angus Glen Golf Club (north of Toronto), the home to the 2007 Canadian Open PGA golf tournament.
"O24 has received an enthusiastic response from golfers who have found its strong and quick pain relief to be very effective to deal with pain and stiffness, both on and off on the Golf Course," stated Kevin Thistle, Vice President/General Manager of Angus Glen Golf Club.
About Swiss Medica, Inc.
Swiss Medica is a specialty pharmaceutical company focused on commercializing over-the-counter clinically-tested, patented all-natural products that relieve chronic ailments. Swiss Medica builds its brands through innovative and focused distribution and marketing strategies. Swiss Medica's mission is to be a world leader in the commercialization of over-the-counter, safe and effective chronic ailment treatments. Please visit our websites at www.swissmedica.com, www.O24zone.com and www.pmsescape.com.
Swiss Medica's flagship product, the O24 Essential Oil Pain Neutralizer, holds U.S. Patent No. 6,444,238B1. The O24 pain relief solution has been used and recommended for its fast-acting and long-lasting benefits by healthcare professionals and athletes in the United States, Canada and in Europe. O24 is widely available over-the-counter throughout the United States and Canada in leading pharmacies and other retailers. Customers can also visit www.O24zone.com for ordering details and store locators for the nearest pharmacy.
Swiss Medica has recently launching the patented O24 Fibromyalgia pain reliever (U.S. Patent No. 6,444,238B1) over-the-counter in North American retailers. The National Fibromyalgia Association (NFA) recently awarded O24 Fibromyalgia their first NFA Seal of Approval. Over 10 million Americans suffer from the long-term pain associated with Fibromyalgia. In a randomized double blind clinical trial conducted in 2005, 88 percent of the patients who used O24 Fibromyalgia reported mild to markedly better improvement, versus only 7 percent who used the placebo. Customers can also visit www.O24zone.com, for ordering details and store locators for the nearest retailer.
Swiss Medica also distributes PMS Escape(r) which holds U.S. Patent Nos. 5760014 and 5612320. PMS Escape(r) is a specially formulated group of carbohydrates, vitamins and minerals, clinically proven to reduce changes in mood and appetite that women experience during the premenstrual period. Customers can also visit: www.pmsescape.com for additional information and ordering details.
Forward-looking statements in this news release are made pursuant to the "Safe Harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, risks relating to acceptance of Swiss Medica's products in Canada, the United States and other countries, risks related to international sales and purchases and potential foreign currency exchange fluctuations, acceptance of Swiss Medica's products, increased levels of competition, dependence on intellectual property rights and other risks detailed from time to time in Swiss Medica's periodic reports filed with the United States Securities and Exchange Commission and other regulatory authorities.